The stock's rise snapped a three-day losing streak.

Shares of Revvity Inc. RVTY slipped 1.08% to $110.32 Thursday, on what proved to be an all-around grim trading session for ...

Revvity (RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software ...

The market seemed underwhelmed by last week's earnings announcement from Revvity, Inc. (NYSE:RVTY) despite the healthy numbers. Our analysis suggests that shareholders might be missing some ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus ...

WALTHAM, Mass., February 20, 2025--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction ...

Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Revvity, Inc. has a fifty-two week low of $97.32 and a fifty-two week high of $129.50. The stock has a market cap of $14.17 billion, a P/E ratio of 53.37, a P/E/G ratio of 3.82 and a beta of 1.06.

Revvity, Inc. (NYSE:RVTY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports.

Company expands infectious disease diagnostics portfolio with first of several assays validated for dried blood spots as sample material Revvity, Inc. (NYSE: RVTY), today announced the launch of ...

In its fourth quarter 2024 investor letter, Bretton Fund emphasized stocks such as Revvity, Inc. (NYSE:RVTY). Revvity, Inc. (NYSE:RVTY) offers health sciences solutions, technologies, and services.